Recurrent Endometrial Carcinoma Completed Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Endometrial Carcinoma, Recurrent

IndicationStatusPhase
DBCOND0028796 (Recurrent Endometrial Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00301964Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial CancerTreatment
NCT00723255Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial CancerTreatment